Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1059 of 6351
-
New drug cocktail shows promise for tough blood cancer
Disease control OngoingThe proposed study is a single-arm, multi-center, open-label phase II study of the combination of palbociclib and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate the efficacy of this combination, with the primary objective of the study being to asse…
Phase 2 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New combo aims to halt early blood cancer before it worsens
Disease control Recruiting nowThis phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for ce…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Bone drug may supercharge immunotherapy against tough melanoma
Disease control CompletedThis is a multicenter open-label, single-arm, phase II study designed to investigate the pharmacodynamic and antitumor effects of denosumab alone and in combination with an anti-Programmed death-1 or Programmed death ligand 1 (PD1) agent (pembrolizumab or nivolumab) in patients w…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
DNA vaccine and immunotherapy combo aims to halt prostate cancer recurrence
Disease control OngoingThe purpose of this study is to evaluate the safety of an investigational DNA vaccine, pTVG-HP, a plasmid DNA encoding human prostatic acid phosphatase (PAP), in combination with nivolumab, and the efficacy of this combination in decreasing serum Prostate-Specific Antigen (PSA) i…
Phase 2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for kids with tough leukemia: targeted drug shows promise
Disease control OngoingThis phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for c…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New cocktail shows promise for tough lung cancer
Disease control CompletedThis is an open-label Phase I/II study, with a dose escalation part (Phase I) and a single-arm part (Phase II), in patients with recurrent SCLC who progressed after first-line platinum-based chemotherapy and who are candidates for second line therapy. No PK evaluation is planned …
Phase 1/2 • Sponsor: Salma Sabbour • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New gene therapy combo shows promise in ovarian cancer trial
Disease control OngoingThis is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.
Phase 1/2 • Sponsor: Imunon • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New device offers hope for back pain sufferers who Can't go under the knife
Symptom relief CompletedThis study is being conducted to document the safety, clinical effectiveness and cost-effectiveness of high-frequency SCS at 10 kHz (HF10™ Therapy) delivered through the Senza system in subjects with chronic refractory back pain (with or without leg pain) who are not considered c…
Sponsor: Nevro Corp • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Can a new immune system fix T-Cell diseases? trial tests donor transplants
Disease control OngoingBackground: Blood stem cells in the bone marrow make all the cells to normally defend a body against disease. Allogeneic blood or marrow transplant is when these stem cells are transferred from one person to another. Researchers think this treatment can provide a new, healthy im…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Promising combo targets tough lymphoma in seniors
Disease control CompletedProspective, multicenter, phase II trial designed to evaluate whether the addition of Venetoclax after rituximab, bendamustine and cytarabine (R-BAC) to high risk patients with mantle cell lymphoma improves the results of the standard R-BAC, in terms of Progression Free Survival.
Phase 2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Brain zaps for depression? DBS device tested in 46 patients
Disease control CompletedThe primary objective of this multicenter, randomized, sham-controlled, double blind (patient and observer blinded) clinical trial is to assess the antidepressant effect of Deep Brain Stimulation (DBS) in patients with treatment resistant major depression using the Boston Scienti…
Sponsor: University Hospital Freiburg • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo therapy shows promise for lung cancer patients without chemo
Disease control CompletedThe goal of this study is to explore if, for locally advanced non-small cell lung cancer patients whose tumors have high levels of PD-L1 (a marker associated with benefits from immunotherapy), a combination of immunotherapy and a personalized 4-week radiotherapy course could be m…
Phase 2 • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Immunotherapy after chemo may keep aggressive lymphoma at bay
Disease control OngoingThe prognosis of Diffuse Large B cell Lymphoma (DLBCL) patients with an early relapse is dismal. Atezolizumab has shown promising activity in relapsed DLBCL patients. Toxicity data on atezolizumab are available for \> 6000 patients and is manageable. The assumption of this study …
Phase 2 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Immunotherapy combo shows promise in aggressive breast cancer trial
Disease control OngoingThis phase II multicentre randomized open-label study will assess the safety and efficacy of Pembrolizumab in combination with standard chemotherapy in inflammatory breast cancer. Pembrolizumab will be administered every 3 weeks during the neoadjuvant chemotherapy. Tissue and blo…
Phase 2 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 26, 2026 15:40 UTC
-
Promising drug combo shows progress against advanced breast cancer
Disease control CompletedThis was a randomized, double-blind, placebo-controlled study conducted in Chinese women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer, plus an open-label, single-arm pharmacokinetic (PK) subset in postmenop…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Radioactive drug combo shows promise for advanced prostate cancer
Disease control OngoingThis phase 2 trial studies radium Ra 223 dichloride, hormone therapy and stereotactic body radiation in treating patients with prostate cancer that has spread to other places in the body. Radium Ra 223 dichloride contains a radioactive substance that collects in the bone and give…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Shock therapy: testosterone plus olaparib takes on resistant prostate cancer
Disease control CompletedThis phase II trial studies how well testosterone (enanthate or cypionate) and olaparib work in treating patients with prostate cancer that has progressed despite hormonal therapy. Hormonal therapy, such as leuprolide, may lessen the amount of male sex hormones made by the body. …
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Laser light may stop chemo mouth sores in children
Prevention Recruiting nowTo assess the efficacy of preventive Low-Level Laser Therapy (LLLT) for reducing the incidence of WHO's grade 3-4 oral mucositis in children and young adults receiving chemotherapy regimens associated with a high rate of mucositis: conventional chemotherapy or High Dose Chemother…
Phase 3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Prevention
Last updated Jun 27, 2026 09:02 UTC
-
New drug aims to keep ulcerative colitis in remission
Disease control OngoingThe purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who responded to induction treatment with risankizumab in a prior AbbVie study of risankizumab in UC. This study consists of three sub-studie…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New combo therapy aims to shrink Hard-to-Treat neuroendocrine liver tumors
Disease control CompletedThis pilot phase II trial studies how effective pembrolizumab and liver-directed therapy or peptide receptor radionuclide therapy are at treating patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive tumors that have spread to the liver (liver…
Phase 2 • Sponsor: Nicholas Fidelman, MD • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC